Clinical Pearl

Boceprevir is a new protease inhibitor used to treat HCV, genotype 1.  If a non-cirrhotic, treatment-naive patient (after a 4-week lead-in phase with Peginterferon + Ribavirin) is able to clear virus by treatment week #8, that patient can stop all therapy at week #28. This is a shorter duration than the expected 48 weeks of treatment for HCV genotype 1.

Advertisements
This entry was posted in Clinical Pearl. Bookmark the permalink.

Leave a Reply

Please log in using one of these methods to post your comment:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s